BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

1:01 PM
Dec 08, 2017
 |  BC Week In Review  |  Company News  |  Deals

Collegium gets U.S. commercial rights to Nucynta from Depomed

Depomed Inc. (NASDAQ:DEPO) granted Collegium Pharmaceutical Inc. (NASDAQ:COLL) exclusive, U.S. rights to commercialize its Nucynta tapentadol analgesic franchise, which includes Nucynta tapentadol immediate release and Nucynta ER, an extended-release...

Read the full 121 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >